Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
Advaxis, Inc. (ADXS)
Last advaxis, inc. earnings: 9/9 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.advaxis.com
Company Research
Source: GlobeNewswire
Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to an estimated 11 months with Standard of Care Median overall survival of 33.7 months in all patients treated with ADXS-PSA in combination with KEYTRUDA® PRINCETON, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated results from the combination arm of KEYNOTE-46 (Part B), the Company’s ongoing Phase 1/2 study investigating ADXS-PSA with KEYTRUDA® (pembrolizumab) in patients with metastatic, castrate-resistant prostate cancer (mCRPC) at the ASCO Genitourinary Cancers Symposium in San Francisco, California. The KEYNOTE-46 trial was conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and evaluated ADXS-PSA, one of Advaxis’ Listeria monocytog
Show less
Read more
Impact Snapshot
Event Time:
ADXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXS alerts
High impacting Advaxis, Inc. news events
Weekly update
A roundup of the hottest topics
ADXS
News
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat